Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM1 | P11229 | 7/20 | 0.74 |
| ▸ | MEN1 | O00255 | 1/20 | 0.73 |
| ▸ | LMNA | P02545 | 1/20 | 0.73 |
| ▸ | ALB | P02768 | 1/20 | 0.73 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.73 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.73 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.73 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.73 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.73 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.73 |
| ▸ | CCKBR | P32239 | 4/20 | 0.67 |
| ▸ | CNR1 | P21554 | 1/20 | 0.57 |
| ▸ | NTSR1 | P30989 | 1/20 | 0.57 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.57 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21272248 | 1.00 | CHRM1 (0.74) | CHRM1MEN1LMNAALBKMT2A | |
| SCHEMBL8331379 | 0.92 | CHRM1 (0.62) | CHRM1MEN1LMNAALBKMT2A | |
| SCHEMBL9060504 | 0.87 | LMNA (0.59) | CHRM1MEN1LMNAALBKMT2A | |
| SCHEMBL13323428 | 0.86 | LMNA (0.73) | CHRM1MEN1LMNAALBKMT2A | |
| SCHEMBL10744742 | 0.85 | CHRM1 (1.00) | CHRM1MEN1LMNAALBKMT2A | |
| SCHEMBL10812464 | 0.85 | LMNA (0.74) | CHRM1MEN1LMNAALBKMT2A | |
| Oxazepam SCHEMBL28100675 | 0.85 | LMNA (0.95) | CHRM1MEN1LMNAALBKMT2A | |
| Oxazepam SCHEMBL528376 | 0.84 | LMNA (1.00) | CHRM1MEN1LMNAALBKMT2A | |
| Oxazepam SCHEMBL9614141 | 0.84 | LMNA (1.00) | CHRM1MEN1LMNAALBKMT2A | |
| SCHEMBL3417928 | 0.84 | GABRA1 (1.00) | CHRM1MEN1LMNAALBKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11021448-B2 | 1,3-dihydro-1,4-benzodiazepine-2-thiones for the treatment of CNS related diseases | HOFFMANN-LA ROCHE INC. (US) | 2021-06-01 | — | — | US | disclosed |
| EP-3535253-A1 | 1,3-DIHYDRO-1,4-BENZODIAZEPINE-2-THIONES FOR THE TREATMENT OF CNS RELATED DISEASES | H. Hoffnabb-La Roche Ag (CH) | 2019-09-11 | — | — | EP | disclosed |
| US-20190256478-A1 | 1,3-DIHYDRO-1,4-BENZODIAZEPINE-2-THIONES FOR THE TREATMENT OF CNS RELATED DISEASES | HOFFMANN-LA ROCHE INC. (US) | 2019-08-22 | — | — | US | disclosed |
| EP-1107746-A2 | METHODS OF USING AND COMPOSITIONS COMPRISING DOPAMINE REUPTAKE INHIBITORS | Sepracor Inc. (US) | 2001-06-20 | — | — | EP | disclosed |
| WO-2000010551-A2 | METHODS OF USING AND COMPOSITIONS COMPRISING DOPAMINE REUPTAKE INHIBITORS | SEPRACOR INC. (US) | 2000-03-02 | — | — | WO | disclosed |
| US-5766556-A | SUITABLE ENVIRONMENT FOR SIMULTANEOUS SYNTHESIS OF ORGANIC COMPOUNDS, INORGANIC COMPOUNDS AND ORGANOMETALLIC COMPOUNDS | WARNER-LAMBERT COMPANY (US) | 1998-06-16 | — | — | US | disclosed |
| US-5714127-A | RESERVOIR RACKS WITH REACTION WELLS; GAS DISPERSION TUBES CONTAINING FILTERS; HOLDER BLOCK WITH APERTURES; MANIFOLD | WARNER-LAMBERT COMPANY (US) | 1998-02-03 | — | — | US | disclosed |
| US-5702672-A | REACTION TUBE COMPRISING GAS DISPERSION TUBE HAVING GROUNG GLASS JOINT SECTION | WARNER-LAMBERT COMPANY (US) | 1997-12-30 | — | — | US | disclosed |
| US-5612002-A | SYNTHESIS OF COMPOUNDS | WARNER-LAMBERT COMPANY (US) | 1997-03-18 | — | — | US | disclosed |
| US-5593642-A | CONTAINMENT OF SOLID SUPPORT WITHIN A GAS DISPERSION TUBE | WARNER-LAMBERT COMPANY (US) | 1997-01-14 | — | — | US | disclosed |
| US-5567391-A | MULTICOMPARTMENT CHEMICAL REACTORS | WARNER-LAMBERT COMPANY (US) | 1996-10-22 | — | — | US | disclosed |
| US-5565173-A | USED FOR SOLID-PHASE SYNTHESIS | WARNER-LAMBERT COMPANY (US) | 1996-10-15 | — | — | US | disclosed |
| WO-1996030393-A1 | A METHOD FOR THE SYNTHESIS OF MIXTURES OF COMPOUNDS | WARNER-LAMBERT COMPANY (US) | 1996-10-03 | — | — | WO | disclosed |
| EP-0663856-A1 | APPARATUS AND METHOD FOR MULTIPLE SIMULTANEOUS SYNTHESIS | WARNER-LAMBERT COMPANY (US) | 1995-07-26 | — | — | EP | disclosed |
| US-5324483-A | Apparatus for multiple simultaneous synthesis | WARNER-LAMBERT COMPANY (US) | 1994-06-28 | — | — | US | disclosed |
| WO-1994008711-A1 | APPARATUS AND METHOD FOR MULTIPLE SIMULTANEOUS SYNTHESIS | WARNER-LAMBERT COMPANY (US) | 1994-04-28 | — | — | WO | disclosed |
| US-4689413-A | Triazolo-benzodiazepine-1-ethanamines as diuretics | THE UPJOHN COMPANY (US) | 1987-08-25 | — | — | US | disclosed |
| US-4514407-A | HYPOTENSIVE AND ANTIEDEMIC AGENTS | THE UPJOHN COMPANY (US) | 1985-04-30 | — | — | US | disclosed |
| US-3966793-A | ORTHO-AMINOARYL KETIMINES | CLIN MIDY (FR) | 1976-06-29 | — | — | US | disclosed |
| US-3933794-A | CENTRAL NERVOUS SYSTEM DEPRESSANTS | THE UPJOHN COMPANY (US) | 1976-01-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11021448-B2 | 1,3-dihydro-1,4-benzodiazepine-2-thiones for the treatment of CNS related diseases | CHRM1, CHRM2, CHRM4 | CHRM1 1/4885MEN1 3220/4885LMNA 4098/4885 |
| US-20190256478-A1 | 1,3-DIHYDRO-1,4-BENZODIAZEPINE-2-THIONES FOR THE TREATMENT OF CNS RELATED DISEASES | CHRM1, CHRM2, CHRM4 | CHRM1 1/4885MEN1 3220/4885LMNA 4098/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.